Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 111
Inquire Before Buying

Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 1, 6 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis - Overview
Primary Sclerosing Cholangitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Sclerosing Cholangitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
Acorda Therapeutics Inc
Albireo Pharma Inc
Allergan Plc
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
DURECT Corp
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Noxopharm Ltd
Sancilio & Company Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shire Plc
Sirnaomics Inc
Primary Sclerosing Cholangitis - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
berberine ursodeoxycholate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Liver Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9674 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-7314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
timolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Sclerosing Cholangitis - Dormant Projects
Primary Sclerosing Cholangitis - Discontinued Products
Primary Sclerosing Cholangitis - Product Development Milestones
Featured News & Press Releases
Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Apr 18, 2018: Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
Apr 13, 2018: NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis
Apr 09, 2018: Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
Feb 26, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis
Feb 20, 2018: DURECT to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)
Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)
Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Oct 23, 2017: Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting 2017
Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
Oct 11, 2017: Intercept Announces Data to be Presented at The Liver Meeting 2017
Sep 25, 2017: Intercept Statement Regarding Ocaliva (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis Patients
Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis
Jul 31, 2017: Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H2 2018
Primary Sclerosing Cholangitis - Pipeline by DURECT Corp, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Noxopharm Ltd, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H2 2018
Primary Sclerosing Cholangitis - Dormant Projects, H2 2018
Primary Sclerosing Cholangitis - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global (United States, European Union and China) Diarrhea Drug Market Research Report 2019-2025
    Published: 17-May-2019        Price: US 3280 Onwards        Pages: 110
    In 2019, the market size of Diarrhea Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Diarrhea Drug. This report studies the global market size of Diarrhea D......
  • Global (United States, European Union and China) Esomeprazole Market Research Report 2019-2025
    Published: 16-May-2019        Price: US 3280 Onwards        Pages: 115
    In 2019, the market size of Esomeprazole is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Esomeprazole. This report studies the global market size of Esomeprazole......
  • Global (United States, European Union and China) Lansoprazole Market Research Report 2019-2025
    Published: 14-May-2019        Price: US 3280 Onwards        Pages: 127
    In 2019, the market size of Lansoprazole is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Lansoprazole. This report studies the global market size of Lansoprazole......
  • Global Irritable Bowel Syndrome (IBS) Market Professional Survey 2019 by Manufacturers, Regions, Types and Applications, Forecast to 2024
    Published: 14-May-2019        Price: US 2600 Onwards        Pages: 152
    In this report, we analyze the Irritable Bowel Syndrome (IBS) industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We......
  • Global Irritable Bowel Syndrome (IBS) Market Data Survey Report 2013-2025
    Published: 13-May-2019        Price: US 1500 Onwards        Pages: 58
    Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled internat......
  • Global Proglumide Market Data Survey Report 2013-2025
    Published: 11-May-2019        Price: US 1500 Onwards        Pages: 64
    Summary The global Proglumide market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers profile, products & services, sales data of business Global market size by Major Application Global market size by Major Type Key manufacturers are included based on company profile, sale......
  • Global Gastroparesis Drugs Market Size, Status and Forecast 2019-2025
    Published: 10-May-2019        Price: US 3900 Onwards        Pages: 98
    Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. The idiopathic gastroparesis segment dominated the global gastroparesis drugs market during 2017 and the segment is expected to continue its dominance during the next few years as well. The market is witnessing the development of new and effective therapies for the symptomatic control of idiopathic gastroparesis, which will be one of the major factors r......
  • Global Gastrointestinal OTC Drugs Market Size, Status and Forecast 2019-2025
    Published: 10-May-2019        Price: US 3900 Onwards        Pages: 91
    Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country. In 2018, the global Gastrointestinal OTC Drugs market size was xx million US$ and it is e......
  • Global Drugs for Traveler's Diarrhea Market Analysis 2013-2018 and Forecast 2019-2024
    Published: 07-May-2019        Price: US 2980 Onwards        Pages: 75
    Summary The global Drugs for Traveler's Diarrhea market will reach xxx Million USD in 2019 and CAGR xx% 2019-2024. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Drugs for Traveler's Diarrhea by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are c......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs